Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

92 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

CSL, CSL LIMITED
nipper
post Posted: Apr 7 2020, 01:21 PM
  Quote Post


Posts: 6,940
Thanks: 2375


Covid-19 response
QUOTE
Clinical trials of unbranded hyperimmune serum could begin ­“within months”, CSL chief scientific ­officer Andrew Cuthbertson said. An effective vaccine able to protect the entire population takes at least 12 months to ­develop.

Professor Cuthbertson said well-designed trials would guide decisions about who would be first in the queue for serum treatment, which is based on “borrowing” the antibodies of patients whose immune systems have fought off the viral illness.

“Probably people who are very high risk, maybe people who are infected and getting worse and heading for the ­intensive care unit, possibly in the ICU. “It could also be used as a preventative treatment if someone coughed right into the face of a health worker.”

Debate on priorities

He said priorities for eligibility in trials and for treatment would involve “great debate”.

“It’s a matter of how do we best use these precious initial vials of this medicine, because we won’t be able to make enough to protect the entire population — you need a vaccine to do that.”

The global pooling of expertise and resources for the manufacture of the hyperimmune treatment was announced on Monday night, with CSL subsidiary CSL Behring and Takeda joined by the German-headquartered Biotest, LFB (France), Octapharma (Switzerland) and Bio Products Laboratory (Britain).

The humanitarian alliance between commercial rivals is open to other firms and plans to work with governments.

“Unprecedented times call for bold moves,” said Julie Kim, president of Takeda’s Plasma-Derived Therapies Business Unit.

Professor Cuthbertson said he expected clinical trials in the northern hemisphere and Australia could start in parallel, with sharing of data and insights speeding up progress.

He said local trials might require 100 to 500 donors, and would require the development of tests enabling identification of the best donors and the potency of antibodies against the illness.

CSL was in talks with the federal Health Department, regulator Therapeutic Goods Administration, research partners including the Melbourne-based Peter Doherty Institute for Infection and Immunology, and plasma collection agency the Australian Red Cross Lifeblood to get trials on foot as soon as possible.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Feb 12 2020, 07:43 AM
  Quote Post


Posts: 6,940
Thanks: 2375


CSL achieved 11 per cent net profit growth of $US1.248 billion and earnings of $US2.75 a share.

The company declared an interim dividend of US95¢ and forecast 2019-20 net profit of $US2.11 billion to $US2.17 billion, up 10 to 13 per cent year-on-year



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Feb 6 2020, 09:09 AM
  Quote Post


Posts: 6,940
Thanks: 2375


In Reply To: nipper's post @ Jan 16 2020, 09:09 AM

and through $320.

(being in the flu vaccine biz, with a coronavirus around, wouldn't be hurting)




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 16 2020, 09:09 AM
  Quote Post


Posts: 6,940
Thanks: 2375


well, CSL hit $300.00 soon after the opening bell this morning.
There was a quick retreat from there, almost to be expected. Mere observer sport, really, but something to write about




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 6 2020, 01:20 PM
  Quote Post


Posts: 6,940
Thanks: 2375


QUOTE
A research note out of Morgan Stanley suggests CSL shares could hit $290 over the next 12 months with a bull case valuation of $359. The key to the bull case valuation is the healthcare giant's Phase 3 trial drug candidate CSL 112 as a treatment for heart attack patients.

It has three potential "catalytic events" over the next 18 months according to the analysts.

Morgan Stanley is forecasting the group will deliver $US4.68 in earnings per share (EPS) over fiscal 2020 on revenue of US$9,129 million. For fiscal 2021 it expects EPS to climb to $US5.50 on revenue of $US10,231 million.

In total it's tipping growing immunoglobulin sales to help deliver a 3-year compound EPS annual growth rate of 13 per cent with fiscal 2020 "above or at the top end of guidance.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 30 2019, 09:37 AM
  Quote Post


Posts: 6,940
Thanks: 2375


Heart-stopper: CSL's $800m heart attack trial
As far as investments go, CSL Limited's $800 million all-or-nothing bet on a treatment to stop recurrent cardiovascular events is a heart-stopper.

http://www.smh.com.au/business/heart-stopp...53iog.html?btis



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

Featured Stock Stories





plastic
post Posted: Dec 19 2019, 05:01 PM
  Quote Post


Posts: 10,012
Thanks: 299


In Reply To: mullokintyre's post @ Dec 19 2019, 01:59 PM

A misspelled one. Doesn't detract from the point I make however. The point of confusion was that both were/are federally sponsored. As are NZ's CRI's.

Imagine how the original investors must be feeling now. They must be in all the best graveyards around town.




--------------------
What did Uncle Mel do to us?
 
jacsar
post Posted: Dec 19 2019, 02:33 PM
  Quote Post


Posts: 822
Thanks: 125


In Reply To: jacsar's post @ Dec 19 2019, 02:30 PM

both formed 1916...my apologies

 
jacsar
post Posted: Dec 19 2019, 02:30 PM
  Quote Post


Posts: 822
Thanks: 125


In Reply To: nipper's post @ Dec 19 2019, 09:58 AM

A simple search.... https://en.wikipedia.org/wiki/CSL_Limited

 
mullokintyre
post Posted: Dec 19 2019, 01:59 PM
  Quote Post


Posts: 2,433
Thanks: 866


In Reply To: nipper's post @ Dec 19 2019, 09:58 AM

QUOTE
you copralitic dufus.

Would have to be the insult of the year.
Mick



--------------------
sent from my Olivetti Typewriter.
 
 


92 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING